Healthcare | May 11, 2026
Sebia India and CAHO launch autoimmunity masterclass series
The six-part webinar series aims to enhance awareness, diagnosis, and management of autoimmune diseases
The six-part webinar series aims to enhance awareness, diagnosis, and management of autoimmune diseases
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The approval was driven by data from the Phase III TULIP-SC trial
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The trial also demonstrated significant improvements across multiple secondary endpoints
Capital infusion to accelerate Earendil’s R&D platform
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
